Genes and (Common) Pathways Underlying Drug Addiction

Chuan-Yun Li, Xizeng Mao, Liping Wei*

Center for Bioinformatics, National Laboratory of Protein Engineering and Plant Genetic Engineering, College of Life Sciences, Peking University, Beijing, People’s Republic of China

Drug addiction is a serious worldwide problem with strong genetic and environmental influences. Different technologies have revealed a variety of genes and pathways underlying addiction; however, each individual technology can be biased and incomplete. We integrated 2,343 items of evidence from peer-reviewed publications between 1976 and 2006 linking genes and chromosome regions to addiction by single-gene strategies, microarray, proteomics, or genetic studies. We identified 1,500 human addiction-related genes and developed KARG (http://karg.cbi.pku.edu.cn), the first molecular database for addiction-related genes with extensive annotations and a friendly Web interface. We then performed a meta-analysis of 396 genes that were supported by two or more independent items of evidence to identify 18 molecular pathways that were statistically significantly enriched, covering both upstream signaling events and downstream effects. Five molecular pathways significantly enriched for all four different types of addictive drugs were identified as common pathways which may underlie shared rewarding and addictive actions, including two new ones, GnRH signaling pathway and gap junction. We connected the common pathways into a hypothetical common molecular network for addiction. We observed that fast and slow positive feedback loops were interlinked through CAMKII, which may provide clues to explain some of the irreversible features of addiction.

Introduction

Drug addiction, defined as “the loss of control over drug use, or the compulsive seeking and taking of drugs despite adverse consequences,” has become one of the most serious problems in the world [1]. It has been estimated that genetic factors contribute to 40%–60% of the vulnerability to drug addiction, and environmental factors provide the remainder [2]. What are the genes and pathways underlying addiction? Is there a common molecular network underlying addiction to different abusive substances? Is there any network property that may explain the long-lived and often irreversible molecular and structural changes after addiction? These are all important questions that need to be answered in order to understand and control drug addiction.

Knowing the genes and vulnerable chromosome regions that are related to addiction is an important first step. Over the past three decades, a number of technologies have been used to generate such candidate genes or vulnerable chromosome regions. For example, in hypothesis-driven studies, genes in different brain regions were selectively expressed, downregulated, or knocked out in animal models of addiction [3]. Recent high-throughput expression-profiling technologies such as microarray and proteomics analyses identified candidate genes and proteins whose expression level changed significantly among different states in addiction [4,5]. Finally, genetic studies such as animal Quantitative Trait Locus (QTL) studies, genetic linkage studies, and population association studies identified chromosomal regions that may contribute to vulnerability to addiction [6–8]. However, as addiction involves a wide range of genes and complicated mechanisms, any individual technology platform or study may be limited or biased [3,9–14]. There is a need to combine data across technology platforms and studies that may complement one another [3,15,16]. The resultant gene list, preferably in a database form with additional functional information, would be a valuable resource for the community. Systematic and statistical analysis of the genes and the underlying pathways may provide a more complete picture of the molecular mechanism underlying drug addiction.

Although different addictive drugs have disparate pharmacological effects, there are also similarities after acute and chronic exposure such as acute rewarding and negative emotional symptoms upon drug withdrawal [17]. Recently it was asked “Is there a common molecular pathway for addiction?” because elucidation of common molecular pathways underlying shared rewarding and addictive actions may help the development of effective treatments for a wide range of addictive disorders [17]. Several individual pathways have been proposed as common pathways [17]; however, they have not been studied systematically and statistically.

Key behavioral abnormalities associated with addiction are long-lived with stable and irreversible molecular and structural changes in the brain, implying a “molecular and structural switch” from controlled drug intake to compulsive...
Related Genes Statistically Significantly Enriched Pathways in Addiction-

Addiction-Related Genes to Date

Most Comprehensive Collection and Database of Results

process. The explosion of genomic and proteomic data in recent years both enabled and necessitated bioinformatic studies of addiction. We integrated data derived from multiple technology platforms and collected 2,343 items of evidence linking genes and chromosome regions to addiction. We identified 18 statistically significantly enriched molecular pathways. In particular, five of them were common for four types of addictive drugs, which may underlie shared rewarding and addictive actions, including two new ones, GnRH signaling pathway and gap junction. We connected the common pathways into a hypothetical common molecular network for addiction. We observed that fast and slow positive feedback loops were interlinked through CAMKII, which may provide clues to explain some of the irreversible features of addiction.

Results

Most Comprehensive Collection and Database of Addiction-Related Genes to Date

As currently the information is scattered in literature, we retrieved and reviewed more than 1,000 peer-reviewed publications from between 1976 and 2006 linking genes and chromosome regions to addiction. In total, we collected 2,343 items of evidence linking 1,500 human genes to addiction. The detailed statistics is shown in Figure 1 and Table S1. A Knowledgebase of Addiction-Related Genes (KARG) is made publicly available at http://karg.cbi.pku.edu.cn. A description of the database statistics is given in Table S1, and the functional annotation fields are listed in Table S2. Two screenshots of the database user interface are shown in Figures S1 and S2. The interface supports browsing of the genes by chromosome or pathways, advanced text search by gene ID, organism, type of addictive substance, technology platform, protein domain, and/or PUBMED ID, and sequence search by BLAST similarity [20]. All data, database schema, and MySQL commands are freely available for download at http://karg.cbi.pku.edu.cn/download.php.

Statistically Significantly Enriched Pathways in Addiction-Related Genes

We analyzed in detail 396 genes that were supported by two or more independent items of evidence. We found that 18 pathways were statistically significantly enriched in addic-

drug abuse [18]. It was proposed that the progress of addiction may involve positive feedback loops that were known to make continuous processes discontinuous and reversible processes irreversible [19]. Once a common molecular network for addiction is constructed, we can look for the existence of positive feedback loops in the network and study the coupling between the loops. It may provide clues to explain the network behaviour and the addiction process.

Common Molecular Pathways for Drug Addiction

Because we collected metadata about each item of evidence linking genes to addiction, in particular the nature of the addictive substance, we could ask next what are the pathways underlying addiction to each type of substance, and what are the common pathways among them. We identified five pathways shared by all four addictive substances (Table 2). Three of the pathways had been linked to addictive behaviors in previous studies and were statistically confirmed here. For example, “long-term potentiation” had been linked to addiction-induced adaptations in glutamatergic transmission and synaptic plasticity [21]. In particular, a core component of this pathway, CAMKII, had been reported to regulate neurite extension and synapse formation through regulation of the actin cytoskeleton [22], providing possible explanations for morphological changes triggered by addictive drugs [17]. This pathway was also considered a key molecular circuit underlying the memory system, highlighting the possible shared mechanisms between drug addiction and the learning and memory system [23]. “MAPK signaling pathway” is another example, as previous studies had suggested its roles in regulating synaptic plasticity related to long-lasting changes in both memory function and addictive properties [24].

More interestingly, two other common pathways identified here had not been directly linked to addiction. “GnRH signaling pathway” was reported to activate gene expression and secretion of gonadotropins and regulate stress pathways in the hypothalamo-pituitary gonadal axis and mammalian reproduction [25]. It is reasonable to hypothesize that the pathway may also be involved in the regulation and control of certain emotional behaviors in addiction such as stress-induced drug-seeking. Another common pathway identified in our study, “Gap junctions”, can be regulated directly by three addiction-related kinases in the “long-term potentiation” pathway, PKA, PKC, and ERK. Since gap junctions are not only an important type of connection for neuronal cells but also the most prevalent group of electrical synapses in the brain [26], this regulation may imply potential modification of cell communication in addiction. It would be interesting to investigate the roles of these pathways in future experimental studies.

A pathway is in itself a subjective concept, whereas the real systems are dynamic and include wide-ranging crosstalk among functional modules. Connecting the common pathways with additional protein-protein interaction data, we constructed a hypothetical common molecular network for
Positive Feedback Loops in the Network

From the common pathway network we identified four positive feedback loops, shown in Figure 2. We further observed that they interlinked with each other through CAMKII (Figure 2). Two of these positive feedback loops involved signal transduction and would be considered “fast” loops, whereas the other two loops involved transcription and translation and would be considered “slow” loops. It had been reported in a dozen systems, such as budding yeast polarization and *Xenopus* oocyte maturation, that coupled fast and slow positive feedback loops could create a switch that was inducible and resistant to noise and played key roles in discontinuous and irreversible biological processes, features characteristic of addiction [27–29]. It was also known that activation of CAMKII played key roles in the development and maintenance of addiction states [30,31]. Disruption of dendritic CaMKII translation impaired the stabilization of synaptic plasticity and memory consolidation [32,33]. These evidences, taken together, suggested that the fast and slow positive feedback loops interlinked through CAMKII may be essential for the development and consolidation of addiction and may provide a systems-level explanation for some of the characteristics of addictive disorders.

Discussion

The addiction-related genes, (common) pathways, and networks were traditionally studied experimentally. The explosion of genomic and proteomic data in recent years both enabled and necessitated bioinformatic studies of addiction. Integration of data from multiple sources could remove biases of any single technology platform, and statistical and network analysis of the integrated data could...
uncover high-level patterns not detectable in any individual study. For instance, our analysis revealed not only many pathways already implicated in addiction [34–38], but also new ones such as GnRH signaling pathway and gap junction, as well as the coupled positive feedback loops through CAMKII. They could serve as interesting hypotheses for further experimental testing.

The collection of addiction-related genes and pathways in KARG, the first bioinformatic database for addiction, is the most comprehensive to date. However, as new technologies continue to be developed and used, more and more genes will be linked to addiction. In 2004, a paper asked why proteomics technology was not introduced to the field of drug addiction [5]; since then eleven studies have identified about 100 differentially expressed proteins in drug addiction. Tilling-array technology, another new strategy for whole-genome identification of transcription factors binding sites, has been used to identify targets of CREB, an important transcription factor implicated in drug addiction [39]. In addition, as 100 K and 500 K SNP arrays have been introduced recently, whole genome association studies will also identify more closely packed and unbiased hypothesis-free vulnerable positions [40]. We will continue to integrate new data and update the gene list and molecular pathways toward a better understanding of drug addiction.

Materials and Methods

Collection of addiction-related genes. The data collection pipeline is summarized in Figure 1. The data and knowledge linking genes and chromosome regions to addiction were extracted from reviewing more than 1,000 peer-reviewed publications from between 1976 and 2006. This list of publications, available on KARG Web site at http://karg.chi.pku.edu.cn/smid.php, included recent review papers on addiction selected from results of PUBMED query (‘addiction OR “drug abuse”) AND review” as well as research papers selected from PUBMED query (‘addiction OR “drug abuse”) AND (gene OR microarray OR proteomics OR QTL OR “population association” OR “genetic linkage”). The data spanned multiple technology platforms including classical hypothesis-testing of single genes, identification of significantly differentially expressed genes in microarray experiments, identification of significantly differentially expressed proteins in proteomics assays, identification of addiction-vulnerable chromosome regions in animal QTL studies, genetic linkage studies, population association studies, and OMIM annotations [41]. From each publication we collected the genes, proteins, or chromosome regions linked to addiction, as well as metadata such as species, nature of the addictive substance, studied brain regions, technology platforms, and experimental parameters. For candidate genes or chromosomal regions identified in mouse or rat, we mapped them to human genes through ortholog mapping by Homologene or syntenic mapping, respectively [41]. For chromosome regions identified in genetic studies, we identified candidate genes when at least one positive marker lay (i) within the gene or (ii) in 3’ or 5’ flanking sequences that were contained on a block of high restricted haplotype diversity along with exon sequences from the same gene [8]. In total, we collected 2,343 items of evidence linking 1,500 human genes to addiction. Among them 396 genes were supported by two or more items of evidence (see full list in Table S4). This more reliable subset was used in subsequent analysis.

Identification of pathways statistically significantly enriched in addiction-related genes. We used the FASTA sequences of the 396 human addiction-related genes as input to the KOBAS software, using all known genes in the human genome as background [42,43]. KOBAS had been shown to lead to experimentally validated pathways [44]. It maps the input sequences to similar sequences in known pathways in the KEGG database [45] (as determined by BLAST similarity search with evaluated cut off e-values <1e-5, rank ≤10), and then groups the input genes by pathways. Because some pathways are naturally large, they may appear highly represented in a random selection of genes or gene products. To resolve this, KOBAS selects the pathways that are more likely to be biologically meaningful by calculating the statistical significance of each pathway in the input set of genes or gene products against all pathways in the whole genome as background. For each pathway that occurs in the input set of genes or gene products, KOBAS calculates the statistical significance of each pathway in the input set of genes or gene products against all pathways in the whole genome as background.

| Pathways | p-Value | Q-Value |
|----------|---------|---------|
| Long-term depression | 2.1E-07 | 1.1E-05 |
| Gap junction | 1.5E-07 | 1.1E-05 |
| Long-term potentiation | 3.5E-06 | 7.2E-05 |
| Neuroactive ligand-receptor interaction | 2.1E-06 | 7.2E-05 |
| MAPK signaling pathway | 3.1E-06 | 7.2E-05 |
| GnRH signaling pathway | 8.5E-06 | 1.5E-04 |
| Calcium signaling pathway | 4.8E-04 | 7.0E-03 |
| Colorectal cancer | 6.5E-04 | 8.3E-03 |
| Pore ion channels | 2.1E-03 | 0.02 |
| VEGF signaling pathway | 3.2E-03 | 0.03 |
| Glycolysis/Gluconeogenesis | 3.8E-03 | 0.03 |
| Protein folding and associated processing | 3.8E-03 | 0.03 |
| Focal adhesion | 4.4E-03 | 0.03 |
| Insulin signaling pathway | 4.9E-03 | 0.03 |
| Parkinson disease | 6.3E-03 | 0.04 |
| Fc epsilon RI signaling pathway | 6.9E-03 | 0.04 |
| Type II diabetes mellitus | 7.7E-03 | 0.05 |
| Progesterone-mediated oocyte maturation | 9.1E-03 | 0.05 |

Table 2. Common Molecular Pathways Identified in Different Types of Drug Addiction

| Addictive Drugs | Cocaine | Alcohol | Opioids | Nicotine |
|----------------|---------|---------|---------|----------|
| Neuroactive ligand-receptor interaction | p-Value: 5.39E-05 | 3.24E-02 | 2.68E-03 | 7.79E-03 |
| Q-Value: 1.8E-04 | 0.05 | 0.01 | 0.04 |
| Long-term potentiation | p-Value: 3.21E-08 | 8.28E-03 | 1.05E-02 | 8.84E-03 |
| Q-Value: 2.8E-07 | 0.03 | 0.03 | 0.04 |
| GnRH signaling pathway | p-Value: 2.84E-05 | 3.93E-04 | 4.67E-03 | 1.72E-02 |
| Q-Value: 1.2E-04 | 3.6E-03 | 0.02 | 0.05 |
| MAPK signaling pathway | p-Value: 1.28E-04 | 2.97E-04 | 7.34E-05 | 1.10E-02 |
| Q-Value: 3.7E-04 | 3.6E-03 | 5.2E-04 | 0.04 |
| Gap junctions | p-Value: 1.93E-08 | 3.11E-03 | 3.30E-03 | 5.85E-03 |
| Q-Value: 2.8E-07 | 0.01 | 0.01 | 0.03 |
KOBAS counts the total number of genes in the input that are involved in the pathway, named m, and the total number of genes in the whole genome that are involved in the same pathway, named M. If input has n genes and the whole genome has N genes, the p-value of the pathway is calculated using a hypergeometric distribution:

\[ p = 1 - \sum_{i=0}^{n-1} \frac{\binom{M}{i} \binom{N-M}{n-i}}{\binom{N}{n}} \]

KOBAS then performs FDR correction [42] to adjust for multiple testing. Pathways with FDR-corrected Q-value < 0.05 were considered statistically significantly enriched in the input set of addiction-related genes.

**Identification of “common” molecular pathways and network.** For each of the four addictive substances, cocaine, opiate, alcohol and nicotine, we input its list of related genes to KOBAS to identify statistically significantly enriched pathways. Molecular pathways that were identified as significantly enriched for all four addictive substances were selected as common pathways for drug addiction.

We constructed a large molecular network of addiction-related genes with the nodes being the gene products and the links extracted from the KEGG database, the Biomolecular Interaction Network Database (BIND), and Human Interactome Map (HIMAP) [46]. The network was analyzed and visualized by Medusa [47]. We selected a more biologically meaningful sub-network representing only the common pathways identified above.

**Development of a database for addiction-related genes.** We developed a database with MySQL relational schema. Cross-reference to key external databases were included to integrate functional information about the genes, such as gene annotation [41], Gene Ontology annotation [48], interacting proteins [46], and functional domain annotations [49]. In addition, a link was given to the original literature reference in the NCBI PubMed database [41]. We implemented a Web-based user interface of the database using PHP and queries of the database using PHP/SQL query script.

**Supporting Information**

**Figure S1.** Chromosome View of Addiction-Related Genes and Genetic Vulnerability Points for Addiction

In window (A), + and − indicate addiction-related genes on the plus or the minus chain, respectively, while “*” labels addiction-vulnerable points identified in population association studies. Clicking blue + or − in the (A) window links to detailed descriptions of that gene (B), including basic information, evidence implicating it in addiction and various functional annotations. Clicking the red stars links to a detailed description of this genetic vulnerable point (C), including evidence for implication in addiction and functional annotations of.
this point (such as the nearest genes and possible effects on these genes).

References

1. Nestler EJ (2001) Molecular basis of long-term plasticity underlying addiction. Nat Rev Neurosci 2: 119–128.
2. Uhl GR (2004) Molecular genetic underpinnings of human substance abuse vulnerability: likely contributions to understanding addiction as a monogenic process. Neuropharmacology 47 (Supplement 1): 140–147.
3. Goldman D, Oroszi G, Ducci F (2005) The genetics of addictions: uncovering the genes. Nat Rev Genet 6: 521–532.
4. Nestler EJ (2001) Psychogenomics: opportunities for understanding addiction. J Neurosci 21: 8924–8927.
5. Williams K, Wu T, Colangelo C, Nairn AC (2004) Recent advances in neuroproteomics and potential application to studies of drug addiction. Neuropharmacology 47 (Supplement 1): 148–166.
6. Uhl GR (2006) Molecular genetics of addiction vulnerability. NeuroRx 3: 295–301.
7. Uhl GR, Liu QR, Naiman D (2002) Substance abuse vulnerability loci: converging genome scanning data. Trends Genet 18: 420–425.
8. Liu QR, Drgon T, Walther D, Johnson C, Poleskaya O, et al. (2003) Pooled association genome scanning: validation and use to identify addiction vulnerability loci in two samples. Proc Natl Acad Sci U S A 102: 11864–11869.
9. Kislinger T, Cox B, Kannan A, Chugh C, Hu P, et al. (2006) Global survey of organ and organelle protein expression in mouse: combined proteomic and transcriptomic profiling. Cell 125: 173–186.
10. Zhu H, Bilgin M, Snyder M (2003) Proteomics. Annu Rev Biochem 72: 783–812.
11. Lube G, Krapfenbauer K, Fontoulakis M (2003) Proteomics in brain research: potentials and limitations. Prog Neurobiol 69: 195–211.
12. Becker M, Schindler J, Notthwang HG (2006) Neuroproteomics—the tasks ahead. Electrophoresis 27: 2810–2829.
13. Rhodes J, Crabbe JC (2005) Gene expression induced by drugs of abuse. Curr Opin Pharmacol 5: 26–33.
14. Fontoulakis M (2004) Application of proteomics technologies in the investigation of the brain. Mass Spectrom Rev 25: 251–258.
15. Nestler EJ (2006) Genes and addiction. Nat Genet 36: 277–281.
16. Nestler EJ, Landsman D (2001) Learning about addiction from the genome. Nature 409: 834–835.
17. Nestler EJ (2005) Is there a common molecular pathway for addiction? Nat Neurosci 8: 1445–1449.
18. Spanagel R, Heilig M (2005) Addiction and its brain science. Addiction 100: 1813–1822.
19. Ferrell JE, Xiong W (2001) Instability in cell signaling: How to make continuous processes discontinuous, and reversible processes irreversible. Chaos 11: 227–236.
20. Als hops SF, Gish W, Miller W, Myers EW, Lipman DJ (1990) Basic local alignment search tool. J Mol Biol 215: 403–410.
21. Jones S, Bonci A (2005) Synaptic plasticity and drug addiction. Curr Opin Pharmacol 5: 29–25.
22. Fink CC, Bayer KU, Myers JW, Ferrell JE Jr, Schulman H, et al. (2003) Selective regulation of neurite extension and synapse formation by the beta but not the alpha isofrom of CaMKII. Neuron 39: 285–297.
23. Bitner RD, Vengar R, Landau EM (2005) Postsynaptic signaling networks: cellular cogwheels underlying long-term plasticity. Biol Psychiatry 57: 113–119.
24. Wang JQ, Fubish EE, Mao L (2007) Regulation of mitogen-activated protein kinases by glutamate receptors. J Neurochem 100: 1–11.
25. Tilbrook AJ, Turner AL, Clarke IJ (2002) Stress and reproduction: central mechanisms and sex differences in non-rodent species. Stress 5: 83–100.
26. Rela L, Szczupak L (2004) Gap junctions: their importance for the dynamics of the nuclear circuits. Mol Neurobiol 30: 341–357.
27. Brandman O, Ferrell JE Jr, Li R, Meyer T (2005) Interlinked fast and slow positive feedback loops drive neural cell decisions. Science 310: 496–498.
28. Wedlich-Soldner R, Wai SC, Schmidt T, Li R (2004) Robust cell polarity is a dynamic state established by coupling transport and GTPase signaling. J Cell Biol 166: 889–900.
29. Bhatia A, Doree M, Fisher D (2001) The interplay between cyclin-B-Cdc2 kinase (MPF) and MAP kinase during maturation of oocytes. J Cell Biol 166: 889–900.
30. Noda Y, Nabeshima T (2004) Opiate physical dependence and N-methyl-D-aspartate receptors. Eur J Pharmacol 500: 121–128.
31. Tang L, Shukla PK, Wang LS, Wang JZ (2006) Reversal of morphine antinociceptive tolerance and dependence by the acute supraspinal inhibition of Ca(2+)/calmodulin-dependent protein kinase II. J Pharmacol Exp Ther 317: 901–909.
32. Miller S, Yasuda M, Coates JK, Jones Y, Martone ME, et al. (2002) Disruption of dendritic translation of CaMKIIalpha impairs stabilization of synaptic plasticity and memory consolidation. Neuron 36: 507–519.
33. Valjent E, Corbille AG, Bertran-Gonzalez J, Herve D, Girault JA (2006) Inhibition of ERK pathway or protein synthesis during reexposure to drugs of abuse previously learned place preference. Proc Natl Acad Sci U S A 103: 2929–2937.
34. Lamprecht R, LeDouxF (2004) Structural plasticity and memory. Nat Rev Neurosci 5: 45–54.

Table S1. Statistics of the Database

| Source | Description | Value |
|--------|-------------|-------|
| PLoS Computational Biology | www.plsocmpbiol.org | January 2008 | Volume 4 | Issue 1 | e2 |
35. Chao J, Nestler EJ (2004) Molecular neurobiology of drug addiction. Annu Rev Med 55: 113–132.
36. Poon HF, Abdullah L, Mullan MA, Mullan MJ, Crawford FC (2006) Cocaine-induced oxidative stress precedes cell death in human neuronal progenitor cells. Neurochem Int 50: 69–73.
37. Cadet JL, Jayanthi S, Deng X (2005) Methamphetamine-induced neuronal apoptosis involves the activation of multiple death pathways. Review. Neurotox Res 8: 199–206.
38. Farber NB, Olney JW (2003) Drugs of abuse that cause developing neurons to commit suicide. Brain Res Dev Brain Res 147: 37–45.
39. Euskirchen G, Royce TE, Bertone P, Martone R, Rinn JL, et al. (2004) CREB binds to multiple loci on human chromosome 22. Mol Cell Biol 24: 3804–3814.
40. Johnson C, Drgon T, Liu QR, Walther D, Edenberg H, et al. (2006) Pooled association genome scanning for alcohol dependence using 104,268 SNPs: Validation and use to identify alcoholism vulnerability loci in unrelated individuals from the collaborative study on the genetics of alcoholism. Am J Med Genet B Neuropsychiatr Genet 141B: 844–853.
41. Wheeler DL, Barrett T, Benson DA, Bryant SH, Canese K, et al. (2006) Database resources of the National Center for Biotechnology Information. Nucleic Acids Res 34: D173–D180.
42. Mao X, Cai T, Olyarchuk JG, Wei L (2005) Automated genome annotation and pathway identification using the KEGG Orthology (KO) as a controlled vocabulary. Bioinformatics 21: 3787–3793.
43. Wu J, Mao X, Cai T, Luo J, Wei L (2006) KOBAS server: a web-based platform for automated annotation and pathway identification. Nucleic Acids Res 34: W720–W724.
44. Shi YH, Zhu SW, Mao XZ, Feng JX, Qin YM, et al. (2006) Transcriptome profiling, molecular biological, and physiological studies reveal a major role for ethylene in cotton fiber cell elongation. Plant Cell 18: 651–664.
45. Kanehisa M, Goto S, Hattori M, Aoki-Kinoshita KF, Itoh M, et al. (2006) From genomics to chemical genomics: new developments in KEGG. Nucleic Acids Res 34: D354–D357.
46. Alfarano C, Andrade CE, Anthony K, Bahroos N, Bajec M, et al. (2005) The Biomolecular Interaction Network Database and related tools 2005 update. Nucleic Acids Res 33: D418–D424.
47. Hooper SD, Bork P (2005) Medusa: a simple tool for interaction graph analysis. Bioinformatics 21: 4432–4433.
48. Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, et al. (2000) Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat Genet 25: 25–29.
49. Mulder NJ, Apweiler R, Attwood TK, Bairoch A, Bateman A, et al. (2005) InterPro, progress and status in 2005. Nucleic Acids Res 33: D201–D205.